Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.
FAQs
Who owns Pfizer? PFE Stock Ownership - TipRanks.com? ›
The ownership structure of Pfizer (PFE) stock is a mix of institutional, retail and individual investors. Approximately 54.25% of the company's stock is owned by Institutional Investors, 0.26% is owned by Insiders and 45.48% is owned by Public Companies and Individual Investors.
Who owns the majority of Pfizer stock? ›Largest shareholders include BlackRock Inc., Vanguard Group Inc, State Street Corp, Bank Of America Corp /de/, Jpmorgan Chase & Co, Northern Trust Corp, Wellington Management Group Llp, Bank of New York Mellon Corp, Geode Capital Management, Llc, and Price T Rowe Associates Inc /md/ .
What is the price target for PFE in 2025? ›According to analysts, PFE price target is 33.11 USD with a max estimate of 45.00 USD and a min estimate of 27.00 USD.
Is PFE a buy, sell, or hold? ›Pfizer has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 11 hold ratings and 0 sell ratings. What is Pfizer's share price target? The average share price target for Pfizer is €29.76. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
What is the PFE prediction for 2024? ›Pfizer stock prediction for October 2024. The forecast for beginning 30.36 dollars. Maximum price 33.59, minimum 27.85.
Who is the main owner of Pfizer? ›Pfizer is a global pharmaceutical and biotechnology company with headquarters in New York. It developed a successful vaccine against COVID-19. Its top three individual shareholders are Frank A. D'Amelio, Mikael Dolsten, and Albert Bourla.
Does Vanguard Group own Pfizer? ›Hedge funds don't have many shares in Pfizer. The company's largest shareholder is The Vanguard Group, Inc., with ownership of 9.0%. BlackRock, Inc. is the second largest shareholder owning 7.6% of common stock, and State Street Global Advisors, Inc.
What is the future of PFE stock? ›Based on short-term price targets offered by 19 analysts, the average price target for Pfizer comes to $33.21. The forecasts range from a low of $27.00 to a high of $45.00. The average price target represents an increase of 10.44% from the last closing price of $30.07.
How many times a year does PFE pay dividends? ›There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 2.0. Our premium tools have predicted Pfizer Inc.
Who is PFE buying? ›(NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
Is Pfizer over or undervalued? ›
We believe the market is underappreciating the margin expansion based on the cost cuts, and we view Pfizer as undervalued. Following overinvestment during the pandemic, Pfizer is reducing costs to adapt to the slowing demand for covid-19 products.
What is the true value of Pfizer stock? ›The details of how we calculate the intrinsic value of stocks are described in detail here. As of today (2024-09-17), Pfizer's Intrinsic Value: Projected FCF is $51.36. The stock price of Pfizer is $29.83. Therefore, Pfizer's Price-to-Intrinsic-Value-Projected-FCF of today is 0.6.
What drugs is Pfizer working on? ›| COMPOUND NAME i | AREA OF FOCUS i | |
|---|---|---|
| Phase 1 | danuglipron (PF-06882961) current | Internal Medicine |
| Phase 1 | danuglipron (PF-06882961) current | Internal Medicine |
| Phase 1 | Dekavil current | Inflammation & Immunology |
| Phase 1 | felmetatug vedotin (PF-08046048) (SGN-B7H4V) current | Oncology |
| Year | Mid-Year, $ | Year-end, $ |
|---|---|---|
| 2025 | 31.12 | 31.61 |
As of 2024-09-17, the Fair Value of Pfizer Inc (PFE) is -7.61 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 30.07 USD, the upside of Pfizer Inc is -125.3%.
How much will Pfizer stock cost in 2030? ›Based on current technical analysis, Pfizer stock (NYSE: PFE) is projected to reach an average price target of $69.00 by the end of 2030. In an optimistic scenario, driven by strong upward momentum and favorable market conditions, the stock could potentially hit $108.00.
Who are the major shareholders of Vanguard Group? ›| Holder | Shares | Date Reported |
|---|---|---|
| Morgan Stanley | 777.25k | Jun 30, 2024 |
| Invenomic Capital Management, LP | 775.9k | Jun 30, 2024 |
| Shaw D.E. & Co., Inc. | 755.73k | Jun 30, 2024 |
| Cove Street Capital, LLC | 627.75k | Jun 30, 2024 |
| Name | Equities | % |
|---|---|---|
| Vanguard Fiduciary Trust Co. 8.922 % | 13,215,837 | 8.922 % |
| BlackRock Advisors LLC 5.090 % | 7,539,331 | 5.090 % |
| STATE STREET CORPORATION 4.011 % | 5,940,826 | 4.011 % |
| Merrill Lynch International 3.490 % | 5,169,677 | 3.490 % |
Largest shareholders include Baillie Gifford & Co, Primecap Management Co/ca/, Flossbach Von Storch Ag, Harding Loevner Lp, VHCOX - Vanguard Capital Opportunity Fund Investor Shares, BlackRock Inc., HLMIX - Harding Loevner International Equity Portfolio Institutional, Temasek Holdings (Private) Ltd, IBB - iShares ...